A Phase 2 interventional study of IVMED-85 ophthalmic solution, Low Dose and IVMED-85 ophthalmic solution, High dose in Myopia, Progressive, sponsored by iVeena Delivery Systems, Inc.. Not yet recruiting. Open to participants aged 5 Years to 10 Years. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by iVeena Delivery Systems, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the efficacy and safety of a 12-month course of IVMED-85 ophthalmic solution on the treatment of pediatric myopia.
The main aims are:
Participants will use eyedrops twice a day for 12 months. Researchers will compare IVMED 85 (2 doses) to a placebo.
This is a multicenter, randomized, vehicle-controlled, double-masked study conducted in the United States (US) in subjects with pediatric myopia in both eyes.
Approximately 144 subjects will be stratified by age group (5 to 7 years of age; 8 to 10 years of age) and randomized (1:1:1) to one of three investigational products (IPs): IVMED-85 ophthalmic solution low-dose or high-dose; or vehicle ophthalmic solution. The study will use stratified block randomization by age group, with a 1:1:1 allocation within each stratum.
Subjects will administer their assigned IP in both eyes two times a day (BID) for approximately 12 months before entering a non-interventional period of approximately 4 months. Subjects will administer their IP under the supervision of a parent/guardian. Subjects who cannot independently apply IP can have their parent/guardian administer IP for them.
The study eye (SE) will be the more myopic eye. If both eyes are equally myopic in spherical equivalent, the eye with more spherical myopia (and less astigmatism) will be chosen as the study eye. If both eyes are equally myopic and astigmatic, the right eye (OD) will be the study eye.
A Data and Safety Monitoring Committee (DSMC) will be convened and will provide ongoing review of cumulative safety data throughout study conduct, inclusive of a Month 4 interim analysis of unmasked safety data.
71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.
This study's planned enrollment of 144 is above the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.
Browse Myopia, Degenerative studies →iVeena Delivery Systems, Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Nov 16, 2026. See what changed
Subjects who meet all the following inclusion criteria at Visit 1 (Screening/Baseline) will be eligible to enroll in the study. Ocular criteria apply to both eyes.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Total subjects n=48, IVMED-85 low dose BID for 12 months
Drug: IVMED-85 ophthalmic solution, Low Dose
Total subjects n=48, IVMED-85 high dose BID for 12 months
Drug: IVMED-85 ophthalmic solution, High dose
Total subjects n=48, placebo BID for 12 months
Drug: Placebo
Eye drop
Eye drop
Eye drop
Refractive error change from baseline at Month 12
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction) in the SE at Month 12
Time frame: Baseline compared to month 12
Refractive error (spherical equivalent as determined by cycloplegic manifest refraction)
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic manifest refraction) in the SE at Month 12
Time frame: From screening to the end of treatment at 12 months
Change in optical biometrics
Change from baseline in keratometry, axial length, and vitreous chamber depth in the SE at all post-baseline visits
Time frame: From screening to the end of treatment at 12 months
Refractive error at non-final study visits
Change from baseline in myopic refractive error (spherical equivalent as determined by cycloplegic autorefraction and cycloplegic manifest refraction) in the SE at all post-baseline visits other than Month 12
Time frame: From screening to the end of treatment at 12 months
Sub foveal choroidal thickness
Change from baseline in sub foveal choroidal thickness in the SE at Month 12
Time frame: From screening to the end of treatment at 12 months
Accommodative amplitude in the spherical equivalent
Change from baseline in accommodative amplitude in the SE at Month 12
Time frame: From screening to the end of treatment at 12 months
Progression of high myopia
Proportion of subjects with baseline myopia of -5 to -5.75 D progressing to -6.25 or worse at Month 12
Time frame: From screening to the end of treatment at 12 months
Progression of prospectively identified progressive myopia
Myopia progression at Month 12 in subjects prospectively identified at baseline as having progressive myopia, defined as an increase of 0.50 D or more in cycloplegic refractive myopia in the previous year based on historical chart records
Time frame: From screening to the end of treatment at 12 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Feb 2029, 24 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Feb 2024 → Feb 2027, primary completion May 2026 → Feb 2029 and completion Dec 2026 → Jun 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
iVeena Delivery Systems, Inc.